Ontology highlight
ABSTRACT: Rationale
There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum.Objectives
To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality.Methods
PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study.Measurements and main results
Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort.Conclusions
Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.
SUBMITTER: Sin DD
PROVIDER: S-EPMC3114051 | biostudies-literature | 2011 May
REPOSITORIES: biostudies-literature
Sin Don D DD Miller Bruce E BE Duvoix Annelyse A Man S F Paul SF Zhang Xuekui X Silverman Edwin K EK Connett John E JE Anthonisen Nicholas A NA Wise Robert A RA Tashkin Donald D Celli Bartolome R BR Edwards Lisa D LD Locantore Nicholas N Macnee William W Tal-Singer Ruth R Lomas David A DA
American journal of respiratory and critical care medicine 20110107 9
<h4>Rationale</h4>There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum.<h4>Objectives</h4>To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality.<h4>Methods</h4>PARC/CCL-18 was measured in serum samples from individuals w ...[more]